Source:http://linkedlifedata.com/resource/pubmed/id/20962111
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2011-1-7
|
pubmed:abstractText |
Renal tubular cell apoptosis is a critical detrimental event that leads to chronic kidney injury in association with renal fibrosis. The present study was designed to investigate the role of galectin-3 (Gal-3), an important regulator of multiple apoptotic pathways, in chronic kidney disease induced by unilateral ureteral obstruction (UUO). After UUO, Gal-3 expression significantly increased compared with basal levels reaching a peak increase of 95-fold by day 7. Upregulated Gal-3 is predominantly tubular at early time points after UUO but shifts to interstitial cells as the injury progresses. On day 14, there was a significant increase in TdT-mediated dUTP nick end labeling-positive cells (129%) and cytochrome c release (29%), and a decrease in BrdU-positive cells (62%) in Gal-3-deficient compared with wild-type mice. The degree of renal damage was more extensive in Gal-3-deficient mice at days 14 and 21, 35 and 21% increase in total collagen, respectively. Despite more severe fibrosis, myofibroblasts were significantly decreased by 58% on day 14 in the Gal-3-deficient compared with wild-type mice. There was also a corresponding 80% decrease in extracellular matrix synthesis in Gal-3-deficient compared with wild-type mice. Endo180 is a recently recognized receptor for intracellular collagen degradation that is expressed by interstitial cells during renal fibrogenesis. Endo180 expression was significantly decreased by greater than 50% in Gal-3-deficient compared with wild-type mice. Taken together, these results suggested that Gal-3 not only protects renal tubules from chronic injury by limiting apoptosis but that it may lead to enhanced matrix remodeling and fibrosis attenuation.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1522-1466
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
300
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
F245-53
|
pubmed:dateRevised |
2011-4-28
|
pubmed:meshHeading |
pubmed-meshheading:20962111-Animals,
pubmed-meshheading:20962111-Apoptosis,
pubmed-meshheading:20962111-Extracellular Matrix,
pubmed-meshheading:20962111-Fibrosis,
pubmed-meshheading:20962111-Galectin 3,
pubmed-meshheading:20962111-Kidney Diseases,
pubmed-meshheading:20962111-Kidney Tubules,
pubmed-meshheading:20962111-Membrane Glycoproteins,
pubmed-meshheading:20962111-Mice,
pubmed-meshheading:20962111-Myofibroblasts,
pubmed-meshheading:20962111-Receptors, Cell Surface,
pubmed-meshheading:20962111-Ureteral Obstruction
|
pubmed:year |
2011
|
pubmed:articleTitle |
Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis.
|
pubmed:affiliation |
Department of Pediatrics, Seattle Children's Research Institute, University of Washington, Division of Nephrology, 4800 Sand Point Way NE, A7931, Seattle, WA 98105, USA. daryl.okamura@seattlechildrens.org
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|